FDA Grants Approval to Celltrion for Expanded Indication of Actemra Biosimilar to Treat CRS

FDA Grants Approval to Celltrion for Expanded Indication of Actemra Biosimilar to Treat CRS

The company’s expanded label for Avtozma (tocilizumab-anoh) now includes the treatment of cytokine release syndrome, aligning the therapy with all indications for which Actemra is approved in the US.

FDA Expands Approval of Celltrion’s Biosimilar Avtozma to Include Cytokine Release Syndrome Treatment

The U.S. Food and Drug Administration (FDA) has approve […] The post FDA Expands Approval of Celltrion’s Biosimilar Avtozma to Include Cytokine Release Syndrome Treatment first appeared on GeneOnline News. The post FDA Expands Approval of Celltrion’s Biosimilar Avtozma to Include Cytokine Release Syndrome Treatment appeared first on GeneOnline News.